Regulus Therapeutics Inc. (NASDAQ:RGLS) Q3 2022 Earnings Call Transcript November 10, 2022
Regulus Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.49.
Operator: Hello, and welcome to the Regulus Therapeutics Inc. Q3 2022 Earnings Conference Call. . I would now like to turn the conference over to Chief Financial Officer, Cris Calsada. Please go ahead.
Crispina Calsada: Thank you, and good afternoon, and thank you for joining us to discuss...
